Enfuvirtide

Expert Opinion on Investigational Drugs

Volumn 11, Issue 12, 2002, Pages 1837-1843

  Chen, Ray Y ^a   Kilby, J Michael ^a   Saag, Michael S ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Antiretroviral therapy; Enfuvirtide; Fusion inhibitor; T 20; Viral entry

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR; EFAVIRENZ; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SYNTHETIC PEPTIDE; T 1249; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PEPTIDE FRAGMENT;

ANAMNESIS; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; INJECTION SITE; LIFE CYCLE; MEMBRANE FUSION; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; REVIEW; SIDE EFFECT; TARGET CELL; VIRUS LOAD; VIRUS PARTICLE; VIRUS STRAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CLINICAL TRIALS; HIV ENVELOPE PROTEIN GP41; HUMANS; PEPTIDE FRAGMENTS;

EID: 0036906683     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.12.1837     Document Type: Review

References (27)

1. KWONG PD, WYATT R, ROBINSON J, SWEET RW, SODROSKI J, HENDRICKSON WA: Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing antibody. Nature (1998) 393:648-659.
2. WYATT R, SODROSKI J: The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science (1998) 280:1884-1888.
3. MATTHEWS TJ, WILD C, CHEN CH, BOLOGNESI DP, GREENBERG ML: Structural rearrangements in the transmembrane glycoprotein after receptor binding. Immunol. Rev. (1994) 140:93-104.
4. GALLAHER W, BALL J, GARRY R et al.: A general model of the transmembrane proteins of HIV and other retroviruses. AIDS Res. Hum. Retroviruses (1989) 5:431-440.
5. DELWART E, MOSIALOS G, GILMORE T: Retroviral envelope glycoproteins contain a 'leucine zipper'-like repeat. AIDS Res. Hum. Retroviruses (1990) 6:703-706.
6. WILD C, GREENWELL T, MATTHEWS T: A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses (1993) 9:1051-1053.
7. WILD CT, SHUGARS DC, GREENWELL TK et al.: Peptides corresponding to a predictive alpha-helical domain of HIV-1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad Sci. USA (1994) 91:9770-9774.
8. CHEN CH, MATTHEWS T, MCDANAL C et al.: A molecular clasp in HIV-1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J. Virol. (1995) 69:3771-3777.
9. WILD C, GREENWELL T, SHUGARS D et al.: The inhibitory activity of an HIV-1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res. Hum. Retroviruses (1995) 11:323-325.
10. WILD C, OAS T, MCDANAL C, BOLOGNESI D, MATTHEWS T: A synthetic peptide inhibitor of HIV replication: correlation between solution structure and viral inhibition. Proc. Natl. Acad. Sci. USA (1992) 89:10537-10541.
11. DUBAY J, ROBERTS S, BRODY B et al.: Mutations in the leucine zipper of HIV-1 transmembrane glycoprotein affect fusion and infectivity. J. Virol. (1991) 65:4748-4756.
12. WILD C, DUBAY JW, GREENWELL T et al.: Propensity for a leucine zipper-like domain of HIV-1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. USA (1994) 91:12676-12680.
13. CARR C, KIM PS: A spring-loaded mechanism for the conformational change of influenza hemaglutinin. Cell (1993) 73:823-832.
14. DERDEYN CA, DECKER JM, SFAKIANOS JN et al.: Sensitivity of HIV-1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. (2000) 74:8358-8367.
15. GREENBERG ML, MCDANAL CB, STANFIELD-OAKLEY SA et al.: Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA (2001) (Abstract 473).
16. RIMSKY LT, SHUGAR DC, MATTHEWS T. Determinants of HIV-1 resistance to gp41-derived inhibitory peptides. J. Virol. (2001) 72:986-992.
17. MINK MA, JANUMPALLI S, DAVISON DK et al.: Correlation of gp41 binding and antiviral potencies of the T-20 fusion inhibitor using clinical trial isolate-derived sequences. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA (2001) (Abstract 474).
18. REEVES J, PUFFER B, AHMAD N et al.: Use of entry inhibitors to probe envelope:receptor interactions. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA (2002) (Abstract 82).
19. KILBY JM, HOPKINS S, VENETTA TM et al.: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [see comments]. Nat. Med. (1998) 4(11):1302-1307.
20. KILBY JM, LALEZARI JP, ERON JJ et al.: The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retroviruses (2002) 18(10):685-693.
21. WEI X, DECKER, JM, LIU H et al.: Emergence of resistant Human Immunodeficiency Virus Type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. (2002) 46(6):1896-1905.
22. LALEZARI JP, KILBY JM, ERON JJ et al.: A Phase II clinical study (T20-205) to determine the long-term safety and acceptability of subcutaneously administered enfuvirtide (T-20) - an HIV fusion inhibitor. (2002) (Submitted).
23. LALEZARI J, DRUCKER J, DEMASI R, HOPKINS S, SALGO M: A controlled Phase II trial assessing three doses of T-20 in combination with abacavir, amprenavir, low dose ritonavir, and efavirenz in non-nucleoside naive, protease inhibitor-experienced, HIV-1-infected adults. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA (2001) (Abstract LB5).
24. HENRY, K, LALEZARI J, O'HEARN M et al.: Enfuvirtide (T-20) in combination with an optimized background (OB) regimen versus OB alone in patients with prior experience or resistance to three classes of approved antiretrovirals (ARVs) in North America and Brazil. XIV International AIDS Conference, Barcelona, Spain (2002) (Abstract LbOr19B).
25. CLOTET B, LAZZARIN A, COOPER D et al.: Enfuvirtide (T-20) in combination with an optimized background (OB) regimen versus OB alone in patients with prior experience or resistance to three classes of approved antiretrovirals (ARVs) in Europe and Australia. XIV International AIDS Conference, Barcelona, Spain (2002) (Abstract LbOr19A).
26. CHURCH J, CUNNINGHAM C, PALUMBO P, SISTA P, P1005 TEAM: Safety and antiviral activity of chronic subcutaneous administration of T-20 in HIV-1-infected children. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, USA (2001) (Abstract 681).
27. TREMBLAY C, KOLLMAN C, GIGUEL F, CHOU TC, HIRSCH MS: Strong in vitro syndergy observed between the fusion inhibitor T-20 and a CXCR4 blocker, AMD3100. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2000) (Abstract 500).